Administration of a selective retinoic acid receptor-γ agonist improves neuromuscular strength in a rodent model of volumetric muscle loss

Keyphrases

• Rodent Models 100%
• Volumetric muscle Loss 100%
• Neuromuscular Strength 100%
• Retinoic Acid Receptor Agonist 100%
• Palovarotene 75%
• Scar 50%
• Tibialis Anterior muscle 50%
• Isometric Torque 50%
• Defect Sites 50%
• Cellular Response 25%
• Rat Model 25%
• Orally Administered 25%
• Healing 25%
• Regenerative Medicine 25%
• Functional Recovery 25%
• Oral Administration 25%
• Functional Deficits 25%
• Skeletal muscle Injury 25%
• Lewis Rats 25%
• Adjunct Therapy 25%
• Histological Assessment 25%
• Neurostimulation 25%
• Histological Staining 25%
• Therapeutic Delivery 25%
• Full-thickness Defect 25%
• Drug Factors 25%
• Synergistic Potential 25%
• Bioactive Factors 25%
• Skeletal muscle Healing 25%

Medicine and Dentistry

• Retinoic Acid Receptor 100%
• Palovarotene 75%
• Scar Formation 50%
• Tibialis Anterior Muscle 50%
• Isometrics 50%
• Skeletal Muscle 50%
• Medicine 25%
• Adjuvant Therapy 25%
• Limb 25%
• Oral Drug Administration 25%
• Muscle Injury 25%
• Histology 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor Agonist 100%
• Retinoic Acid Receptor 100%
• Palovarotene 75%
• Scar Formation 50%
• Rat Model 25%
• Muscle Injury 25%
• Lewis Rat 25%